ICON delivers comprehensive medical imaging services across a broad range of therapeutic areas. Supported by leading edge technology platforms to streamline image collection, management and analysis, we help clients improve decision making, increase efficiency  and potentially reduce study costs. 

ICON can help to assure the safety of all your clinical trial participants with end-to-end cardiac safety solutions, including electrocardiography (ECG), event monitoring, blood pressure monitoring (BPM), long-term Holter monitoring, echocardiography (ECHO) and multi-gated acquisition scan (MUGA) studies.

Late-stage research for immuno-oncology trials introduces unique challenges. ICON’s specialised services can address these through access to large-scale, patient-reported and real-world data, which can be visualised, aggregated, and analysed. In addition, we employ cutting-edge techniques to link clinical trial data to real-world and third-party data without compromising patients’ identity. The compounding power of tokenisation translates to the accumulation of intelligence, so clinical trials can achieve timely regulatory approval and utilise patient data beyond initial investment for pre-approval and commercialisation.

Webinar: Beyond the Token: Why Your Healthcare Data and Integration Strategy Matters

Whitepaper: The triad of trust: Navigating real-world healthcare data integration

With the rising cost and time to bring new drugs to market, and the need to increase patient diversity and retention, there is increasing demand for decentralised and hybrid immuno-oncology trials. ICON’s commercial connected health platforms, real-world data and information solutions—together with a global site network, home health services and wearables expertise—enable patient-centric decentralised and hybrid trial solutions.

Study endpoints are increasingly complex, and endpoint adjudication is becoming a focal point of regulators. With a key opinion leader network of 650 experts, ICON supports consistent reporting across regions and provides a quality control check through the clinical expert review of principal investigator reporting.

Our adaptable, client-oriented team has developed efficient processes to deliver successful results. Our integrated endpoint management capabilities (eCOA, ePRO), include rating-scale licensing through Mapi Research Trust, the holder of over 5,000 COAs and distributor of more than 600 questionnaires.

Following the acquisition of HumanFirst, ICON's ability to accelerate and improve digital health technology (DHT) selection to optimise protocol design is further enhanced.